Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Intangibles (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Intangibles for 4 consecutive years, with $643000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles fell 19.52% to $643000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $643000.0, a 19.52% decrease, with the full-year FY2024 number at $643000.0, down 40.96% from a year prior.
  • Intangibles was $643000.0 for Q3 2025 at Mereo BioPharma, up from $470000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $33.1 million in Q4 2021 to a low of $470000.0 in Q2 2025.
  • A 4-year average of $4.3 million and a median of $799000.0 in 2024 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 19.52% in 2025; the steepest drop was 45.73% in 2025.
  • Mereo BioPharma's Intangibles stood at $33.1 million in 2021, then plummeted by 96.71% to $1.1 million in 2023, then crashed by 40.96% to $643000.0 in 2024, then changed by 0.0% to $643000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Intangibles are $643000.0 (Q3 2025), $470000.0 (Q2 2025), and $554000.0 (Q1 2025).